Vertex Expands into New Disease Areas and Enhances Gene Editing Capabilities Through Expanded Collaboration with CRISPR Therapeutics and Acquisition of Exonics Therapeutics

134

BOSTON & WATERTOWN, Mass. & ZUG, Switzerland–(BUSINESS WIRE)–Vertex today announced expanded collaboration with CRISPR Therapeutics and acquisition of Exonics Therapeutics to enhance gene editing capabilities.

 

 

http://www.businesswire.com/news/home/20190606005853/en/Vertex-Expands-New-Disease-Areas-Enhances-Gene/